Non-invasive prenatal testing (NIPT) for fetal aneuploidy such as Down syndrome has rapidly transformed the global prenatal screening landscape. In the Netherlands, NIPT is only available within the TRIDENT studies. Aim is to investigate all aspects for responsible implementation of NIPT in the Dutch prenatal screening program.
TRIDENT-1 study (>April 2014)
TRIDENT-1 includes women who are at an elevated risk of carrying a fetus with Down syndrome (or trisomy 18 or 13) based on first trimester combined test (FCT) or medical history. A license was granted after positive advice by the Dutch Health Council.
TRIDENT-2 study (>April 2017)
After the advice of the Dutch Health Council NIPT is offered as first-tier screening test to all ~170,000 pregnant women in The Netherlands. Women are given a choice between FCT, NIPT, or no prenatal screening. To create equal access, both tests are offered at comparable costs. The NIPT is subsidised by the Dutch government.
The nationwide TRIDENT studies evaluate two parts of implementation:
- Part I. Organisation, logistics, outcome, test-performance and costs.
- Part II. Women’s decision-making, uptake, preferences, psychosocial aspects
Both TRIDENT studies end April 2023. A list of publications can be found here.
The TRIDENT studies (TRIal by Dutch Laboratories for Evaluation of Non-invasive Testing) have been designed and are carried out by the NIPT Consortium. This Consortium is membered by all Dutch stakeholders involved in prenatal care including obstetricians, clinical geneticists, midwives, laboratory specialists, the VSOP Dutch Genetic Alliance, ethicists, and researchers. A list of all NIPT consortium members can be found here.
Information about prenatal screening for Down syndrome, Edwards’ syndrome and Patau’s syndrome (for pregnant women in The Netherlands)